Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
- 19 December 2014
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 11 (10), 1180-1190
- https://doi.org/10.1016/j.jalz.2014.10.009
Abstract
Synaptic dysfunction is an early event in Alzheimer's disease (AD) pathogenesis and directly related to cognitive impairment. Consequently, synaptic biomarkers may be valuable tools for both early diagnosis and disease stage. Neurogranin (Ng) is a postsynaptic protein involved in memory consolidation. We developed three monoclonal anti-Ng antibodies. Mass spectrometry and a novel enzyme-linked immunosorbent assay were used to analyze cerebrospinal fluid (CSF) Ng in three independent clinical cohorts including patients with AD dementia (n = 100 in total), mild cognitive impairment patients (MCI), (n = 40) and controls (n = 80 in total). We show in three independent clinical cohorts a marked increase in CSF Ng levels in AD dementia (P < .001 in all studies). In addition, high CSF Ng levels at the MCI stage predicted progression to dementia due to AD with a hazard ratio of 12.8 (95% confidence interval 1.6–103.0, P = .02). In amyloid-positive MCI patients, high CSF Ng correlated with a more rapid change in cognition during clinical follow-up (P = .03). These results suggest that CSF Ng is a novel AD biomarker that may be used to monitor synaptic degeneration, and correlates with the rate of cognitive decline in prodromal AD.Keywords
Funding Information
- Vetenskapsrådet (# 14002, K2010‐63P‐21562‐01‐4, K2011‐61X‐20401‐05‐6)
- Knut och Alice Wallenbergs Stiftelse
- Magnus Bergvalls Stiftelse
- Gun och Bertil Stohnes Stiftelse
- Hjärnfonden
- Demensförbundet
- EU Joint Programme – Neurodegenerative Disease Research (BIOMARKAPD)
- Alzheimer Nederland (WE.15‐2013‐08)
This publication has 38 references indexed in Scilit:
- Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s DiseasePLOS ONE, 2013
- Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS MethodNeurochemical Research, 2011
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly PeopleArchives of Neurology, 2010
- Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluidExperimental Neurology, 2010
- Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s diseaseActa Neuropathologica, 2010
- A consensus protocol for the standardization of cerebrospinal fluid collection and biobankingNeurology, 2009
- Alzheimer's diseaseThe Lancet, 2006
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 alleleJournal of Neural Transmission, 1996
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991